JGJean-Baptiste Gibier

Jean-Baptiste Gibier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jean-Baptiste Gibier has a total of 259 co-authors. Here are the top co-authors by number of shared publications:

  • Viviane Gnemmi

    Department of Pathology, CHU de Nantes, Nantes France

    8 shared publications
  • Marie-Christine Copin

    UMR9020 - UMR-S 1277, Inserm, CNRS, pathology department, cancer heterogeneity, plasticity and resistance to therapies, Canther, CHU de Lille, Institut Pasteur de Lille, université Lille, 59000 Lille, France

    7 shared publications
  • Christelle Cauffiez

    Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France

    5 shared publications
  • François Glowacki

    CHU de Lille, service de néphrologie, dialyse, transplantation rénale et aphérère, Lille, France

    4 shared publications
  • Isabelle Van Seuningen

    Inserm UMR-S 1172, Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc), Team “Mucins, Epithelial Differentiation and Carcinogenesis”; University Lille; CHU Lille, 59045, Lille CEDEX, France

    4 shared publications
  • Michaël Perrais

    Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France

    3 shared publications

Latest Publications

  • Open Access

    Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer

    by Alexis B Cortot, Romain Dubois, Valérie Grégoire, Jean‐Baptiste Gibier, Julien Labreuche, Virginie Deprez, Déborah Dubrulle, Thomas Chretien, Eric Wasielewski, Hélène Behal, et al.

    Aims: The c‐Met signalling pathway is dysregulated in non‐small cell lung cancer (NSCLC), with c‐Met protein overexpression emerging as a potentially actionable biomarker given the development of c‐Met‐targeted antibody‐drug conjugates. This retrospective study assessed the consistency of c‐Met protein overexpression over time in patients with non‐squamous NSCLC and two or more longitudinal biopsy samples (one before treatment, one post‐treatment). Methods and results: Samples from 160 patients were analysed for c‐Met protein expression. The concordance rate for c‐Met protein overexpression between samples was 81.3%, indicating most patients had consistent expression status. Patients with an EGFR mutation had a lower concordance rate (65.8%). Fourteen patients with high discordance (negative to positive) between sampling time points showed a high frequency of oncogenic driver alterations, hence often received targeted therapy before the second sample and had high percentages of cells at 2+ intensity in c‐Met immunohistochemistry before treatment. Conclusions: These results indicate c‐Met protein overexpression can be assessed before or after treatment since most patients maintain consistent c‐Met status. As targeted therapies may elevate c‐Met overexpression over time, retesting may be necessary in those with an oncogenic driver alteration initially diagnosed as c‐Met negative.

  • Rôle de la mucine MUC1 en pathologie rénale non tumorale

    by Jean-Baptiste Gibier

    MUC1 est une glycoprotéine exprimée au niveau des tubes distaux et collecteurs du rein adulte. En pathologie rénale, elle est principalement connue pour être exprimée dans certains carcinomes rénaux et en raison de l’existence de mutations du gène responsables d’une forme rare d’insuffisance rénale chronique. Des travaux précédents de notre équipe ont mis en évidence une induction et un rôle néphroprotecteur de MUC1 dans un modèlemurin d’ischémie-reperfusion (IR). Afin de compléter les données sur le rôle de MUC1 dansce modèle, nous avons spécifiquement étudié l’expression de MUC1 au niveau des tubesproximaux qui sont à l’origine des propriétés uniques de régénération du rein. Nous avonsmontré que MUC1 est induit dans les cellules épithéliales tubulaires et que son expressions’associe à une transition épithélio-mésenchymateuse (TEM) partielle qui est à l’origine de laplus grande plasticité de ces cellules. Par ailleurs, nous avons observé que l’expressionpersistante de MUC1 dans le parenchyme rénal est associée à une réparation incomplètedes lésions parenchymateuses et à l’évolution vers la fibrose interstitielle et la dysfonctionrénale chronique.Dans un deuxième temps de notre travail, nous avons souhaité étudier le rôleimmunomodulateur de MUC1. Dans le modèle d’IR, l’entretien des lésions ischémiques estsecondaire à la mise en place d’une inflammation stérile caractérisée par l’activation del’immunité innée qui succède à la libération de signaux de danger lors de la mort des cellulestubulaires. Dans le tractus respiratoire et digestif, il a été montré que MUC1 joue un rôle antiinflammatoirenotamment via l’inhibition des Toll Like Receptors (TLRs), une famille derécepteurs spécialisés dans la reconnaissance de ces signaux de danger. Dans le rein, leTLR4 est le principal TLR impliqué à la fois dans la réponse à l’IR et au sepsis. En utilisantun modèle d’insuffisance rénale aiguë septique par injection de lipopolysaccharide (LPS), unligand spécifique du TLR4, nous avons pu montrer que MUC1 a une action néphroprotectricevia une diminution des signaux inflammatoires. Cette action de MUC1 est secondaire à sonexpression au niveau des macrophages pro-inflammatoires qui jouent un rôle central dans lesepsis. Plus précisément, l’effet anti-inflammatoire de MUC1 découle de l’inhibition durecrutement de la protéine adaptatrice MYD88 dès les premières étapes de la voie du TLR4.Au total, nos résultats montrent que MUC1 joue un rôle préalablement méconnu au cours del’agression rénale aiguë qu’elle soit d’origine ischémique ou septique.

  • Open Access

    Description of peripheral nervous system involvement in wild-type transthyretin amyloidosis: A clinical and electrophysiological study

    by R. Barriol, B. Lemarchant, F. Cassim, J.-B. Davion, L. Defebvre, J.-B. Gibier, N. Lamblin, C. Tard


  • Open Access

    Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: A multicenter international study

    by Dina Zielinski, Valentin Goutaudier, Marta Sablik, Gillian Divard, Olivier Aubert, Alexis Piedrafita, Fariza Mezine, Jessy Dagobert, Anais Certain, Blaise Robin, et al.


  • Open Access

    Performance and limitations of a supervised deep learning approach for the histopathological Oxford Classification of glomeruli with IgA nephropathy

    by Nicola Altini, Michele Rossini, Sándor Turkevi-Nagy, Francesco Pesce, Paola Pontrelli, Berardino Prencipe, Francesco Berloco, Surya Seshan, Jean-Baptiste Gibier, Aníbal Pedraza Dorado, et al.


  • Open Access

    A specific molecular signature in SARS-CoV-2–infected kidney biopsies

    by Pierre Isnard, Paul Vergnaud, Serge Garbay, Matthieu Jamme, Maeva Eloudzeri, Alexandre Karras, Dany Anglicheau, Valérie Galantine, Arwa Jalal Eddine, Clément Gosset, et al.

    Acute kidney injury is one of the most important complications in patients with COVID-19 and is considered a negative prognostic factor with respect to patient survival. The occurrence of direct infection of the kidney by SARS-CoV-2, and its contribution to the renal deterioration process, remain controversial issues. By studying 32 renal biopsies from patients with COVID-19, we verified that the major pathological feature of COVID-19 is acute tubular injury (ATI). Using single-molecule fluorescence in situ hybridization, we showed that SARS-CoV-2 infected living renal cells and that infection, which paralleled renal angiotensin-converting enzyme 2 expression levels, was associated with increased death. Mechanistically, a transcriptomic analysis uncovered specific molecular signatures in SARS-CoV-2–infected kidneys as compared with healthy kidneys and non–COVID-19 ATI kidneys. On the other hand, we demonstrated that SARS-CoV-2 and hantavirus, 2 RNA viruses, activated different genetic networks despite triggering the same pathological lesions. Finally, we identified X-linked inhibitor of apoptosis-associated factor 1 as a critical target of SARS-CoV-2 infection. In conclusion, this study demonstrated that SARS-CoV-2 can directly infect living renal cells and identified specific druggable molecular targets that can potentially aid in the design of novel therapeutic strategies to preserve renal function in patients with COVID-19.


  • Open Access

    Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects

    by Edmone Dewaeles, KévIn Carvalho, Sandy Fellah, Jaewon Sim, Nihad Boukrout, Raphaelle Caillierez, Hariharan Ramakrishnan, Cynthia Van der Hauwaert, Jhenkruthi Vijaya Shankara, Nathalie Martin, et al.

    Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment.


  • Open Access

    A Double-Negative Feedback Interaction between miR-21 and PPAR-α in Clear Renal Cell Carcinoma

    by Marine Goujon, Justine Woszczyk, Kelly Gaudelot, Thomas Swierczewski, Sandy Fellah, Jean-Baptiste Gibier, Isabelle Van Seuningen, Romain Larrue, Christelle Cauffiez, Viviane Gnemmi, et al.

    Clear cell renal cell carcinoma (ccRCC) is the main histotype of kidney cancer, which is typically highly resistant to conventional therapies and known for abnormal lipid accumulation. In this context, we focused our attention on miR-21, an oncogenic miRNA overexpressed in ccRCC, and peroxysome proliferator-activated receptor-α (PPAR- α), one master regulator of lipid metabolism targeted by miR-21. First, in a cohort of 52 primary ccRCC samples, using RT-qPCR and immunohistochemistry, we showed that miR-21 overexpression was correlated with PPAR-α downregulation. Then, in ACHN and 786-O cells, using RT-qPCR, the luciferase reporter gene, chromatin immunoprecipitation, and Western blotting, we showed that PPAR-α overexpression (i) decreased miR-21 expression, AP-1 and NF-κB transcriptional activity, and the binding of AP-1 and NF-κB to the miR-21 promoter and (ii) increased PTEN and PDCD4 expressions. In contrast, using pre-miR-21 transfection, miR-21 overexpression decreased PPAR-α expression and transcriptional activity mediated by PPAR-α, whereas the anti-miR-21 (LNA-21) strategy increased PPAR-α expression, but also the expression of its targets involved in fatty acid oxidation. In this study, we showed a double-negative feedback interaction between miR-21 and PPAR-α. In ccRCC, miR-21 silencing could be therapeutically exploited to restore PPAR-α expression and consequently inhibit the oncogenic events mediated by the aberrant lipid metabolism of ccRCC.


  • A case of transthyretin-related cerebral amyloid angiopathy. The other side of hereditary transthyretin amyloidosis

    by B. Lemarchant, T. Lebouvier, X. Delbeuck, J. B. Gibier, C. Tard

    The target organs for familial transthyretin amyloidosis are typically the nerves, the heart or even the eyes due to the accumulation of amyloid deposits. Less frequently, these deposits can occur within the central nervous system and drive a specific phenotype of cerebral amyloid angiopathy. We report the case of a 72-year-old woman showing evidence of cerebral amyloid angiopathy, in a context of hereditary transthyretin amyloidosis (hATTR) due to p.(Ser77Tyr) mutation of the TTR gene. Her cognitive assessment on a two-year follow-up was remarkably steady. A very limited number of patients with hereditary transthyretin amyloidosis associated with a cerebral amyloid angiopathy have been reported. Few characteristics could distinguish them from classic cerebral amyloid angiopathy, and more data are needed to highlight specific features. Screening for peripheral neuropathy should be considered for patients referred to memory clinic for atypical cerebral amyloid angiopathy.


  • Open Access

    Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study

    by Rémi Lenain, Mehdi Maanaoui, Aghilès Hamroun, Romain Larrue, Cynthia Van Der Hauwaert, Jean-Baptiste Gibier, Viviane Gnemmi, Sébastien Gomis, Myriam Labalette, Franck Broly, et al.

    The pharmacokinetic variability of tacrolimus can be partly explained by CYP3A5 activity. Our objective was to evaluate a tacrolimus sparing policy on renal graft outcome according to CYP3A5 6986A>G genetic polymorphism. This retrospective study included 1114 recipients with a median follow-up of 6.3 years. Genotyping of the 6986A>G allelic variant corresponding to CYP3A5*3 was systematically performed. One year after transplantation, tacrolimus blood trough concentration (C0) target range was 5–7 ng/mL. However, daily dose was capped to 0.10 mg/kg/day regardless of the CYP3A5 genotype. A total 208 CYP3A5*1/- patients were included. Despite a higher daily dose, CYP3A5*1/- recipients exhibited lower C0 during follow-up (p < 0.01). Multivariate analysis did not show any significant influence of CYP3A5*1/- genotype (HR = 0.70, 0.46–1.07, p = 0.10) on patient-graft survival. Glomerular Filtration Rate (GFR) decline was significantly lower for the CYP3A5*1/- group (p = 0.02). The CYP3A5*1/- genotype did not significantly impact the risk of biopsy-proven acute rejection (BPAR) (HR = 1.01, 0.68–1.49, p = 0.97) despite significantly lower C0. Based on our experience, a strategy of tacrolimus capping is associated with a better GFR evolution in CYP3A5*1/- recipients without any significant increase of BPAR incidence. Our study raised some issues about specific therapeutic tacrolimus C0 targets for CYP3A5*1/- patients and suggests to set up randomized control studies in this specific population.